Physician profile
Dudley Bennett
NPI 1730185570
$477.59
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $103.71 | 2019 | |
| Celgene Corporation | $98.67 | 2019 | |
| Amgen INC. | $91.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.06 | 2019-2020 | |
| Ucb, INC. | $47.86 | 2019-2020 | |
| Lilly USA, LLC | $34.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.97 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2020 | |
| Pfizer INC. | $14.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dudley Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.